INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas

Phase 1 Completed 13 enrolled Pediatric Brain Tumor Consortium American Lebanese Syrian Associated Charities · collab National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.

Timeline

Start: 2020-07-27
Primary completion: 2023-12-31
Completion: 2024-12-01

Publications

Park EJ, Lee CW. Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies. Exp Mol Med. 2024 Feb;56(1):100-109. doi: 10.1038/s12276-023-01150-6. Epub 2024 Jan 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INCB7839	Unknown	80 mg/m2	Oral
Subject	INCB7839	Unknown	120 mg/m2	Oral

INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas

Summary

Timeline

Publications

Drugs

Indications